Literature DB >> 17561380

The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production.

Lena Danovich1, Leo Veenman, Svetlana Leschiner, Michal Lahav, Vered Shuster, Abraham Weizman, Moshe Gavish.   

Abstract

It has been shown that the atypical antipsychotic drug clozapine increases the levels of the neurosteroid allopregnanolone in the rat brain. The 18 kDa translocator protein (TSPO), formerly known as the peripheral-type benzodiazepine receptor, has been demonstrated to be involved in the process of steroid biosynthesis, in peripheral steroidogenic tissues as well as in glia cells in the brain. In the current study, we investigated the influence of chronic treatment with clozapine and other antipsychotics (thioridazine,sulpiride and risperidone) on TSPO binding in cell cultures and rat tissues. Clozapine significantly increased TSPO binding density in C6 rat glioma cells and in MA-10 mouse Leydig tumor cells, while the antipsychotic sulpiride had no effect on TSPO binding density in both cell lines. In addition, clozapine, but not sulpiride, significantly increased progesterone synthesis by MA-10 Leydig tumor cells. In an animal experiment, male Sprague-Dawley rats were treated with clozapine (20 mg/kg), risperidone (0.5 mg/kg), thioridazine (20 mg/kg), or sulpiride (20 mg/kg) for 21 days, followed by 7 days of withdrawal. Clozapine induced significant increases in TSPO binding in brain and peripheral steroidogenic tissues, whereas the other antipsychotics did not show such pronounced effects on TSPO binding. Our results suggest that TSPO may be involved in the modulation of steroidogenesis by clozapine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17561380     DOI: 10.1016/j.euroneuro.2007.04.005

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  18 in total

1.  Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28.

Authors:  K Collste; P Plavén-Sigray; H Fatouros-Bergman; P Victorsson; M Schain; A Forsberg; N Amini; S Aeinehband; S Erhardt; C Halldin; L Flyckt; L Farde; S Cervenka
Journal:  Mol Psychiatry       Date:  2017-02-14       Impact factor: 15.992

2.  In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study.

Authors:  S E Holmes; R Hinz; R J Drake; C J Gregory; S Conen; J C Matthews; J M Anton-Rodriguez; A Gerhard; P S Talbot
Journal:  Mol Psychiatry       Date:  2016-10-04       Impact factor: 15.992

3.  Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA.

Authors:  Miran Kenk; Thiviya Selvanathan; Naren Rao; Ivonne Suridjan; Pablo Rusjan; Gary Remington; Jeffrey H Meyer; Alan A Wilson; Sylvain Houle; Romina Mizrahi
Journal:  Schizophr Bull       Date:  2014-11-09       Impact factor: 9.306

4.  The sticky issue of neurosteroids and GABA(A) receptors.

Authors:  Mariangela Chisari; Lawrence N Eisenman; Douglas F Covey; Steven Mennerick; Charles F Zorumski
Journal:  Trends Neurosci       Date:  2010-04-19       Impact factor: 13.837

5.  Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.

Authors:  Christine E Marx; Jimmy Lee; Mythily Subramaniam; Attilio Rapisarda; Dianne C T Bautista; Edwin Chan; Jason D Kilts; Robert W Buchanan; Eu Pui Wai; Swapna Verma; Kang Sim; Jayaraman Hariram; Rajesh Jacob; Richard S E Keefe; Siow Ann Chong
Journal:  Psychopharmacology (Berl)       Date:  2014-07-17       Impact factor: 4.530

Review 6.  Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System.

Authors:  Ayushi Anna Dinesh; Juned Islam; Javad Khan; Federico Turkheimer; Anthony C Vernon
Journal:  CNS Drugs       Date:  2020-09-25       Impact factor: 5.749

Review 7.  Neurosteroids, stress and depression: potential therapeutic opportunities.

Authors:  Charles F Zorumski; Steven M Paul; Yukitoshi Izumi; Douglas F Covey; Steven Mennerick
Journal:  Neurosci Biobehav Rev       Date:  2012-10-17       Impact factor: 8.989

8.  Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.

Authors:  Christine E Marx; Richard S E Keefe; Robert W Buchanan; Robert M Hamer; Jason D Kilts; Daniel W Bradford; Jennifer L Strauss; Jennifer C Naylor; Victoria M Payne; Jeffrey A Lieberman; Adam J Savitz; Linda A Leimone; Lawrence Dunn; Patrizia Porcu; A Leslie Morrow; Lawrence J Shampine
Journal:  Neuropsychopharmacology       Date:  2009-04-01       Impact factor: 7.853

Review 9.  Applicability, potential and limitations of TSPO PET imaging as a clinical immunopsychiatry biomarker.

Authors:  Livia J De Picker; Benno C M Haarman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-18       Impact factor: 9.236

10.  [11C]PBR28 MR-PET imaging reveals lower regional brain expression of translocator protein (TSPO) in young adult males with autism spectrum disorder.

Authors:  N R Zürcher; M L Loggia; J E Mullett; C Tseng; A Bhanot; L Richey; B G Hightower; C Wu; A J Parmar; R I Butterfield; J M Dubois; D B Chonde; D Izquierdo-Garcia; H Y Wey; C Catana; N Hadjikhani; C J McDougle; J M Hooker
Journal:  Mol Psychiatry       Date:  2020-02-19       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.